It is worth-noting, however, that this association was not found in NSCLC patients habouring EGFR mutations, despite the fact that a similar trend was observed [42], thus implying that the modes of action of miR-200c may be apparently distinct between conditions that are receptive/reluctant to gefitinib-induced cytotoxicity. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.